B
Bull
Bull · 25%ELTX
$13.43
Szenariopreis
$2.840
-0.151 (-5.33%)Zum Schluss
Loading chart…
- High
- 3.000
- Open
- 3.000
- VWAP
- 2.89
- Vol
- 421.56K
- Mkt Cap
- 70.76M
- Low
- 2.840
- Amount
- 1.22M
- EV/EBITDA, TTM
- 0.00
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
AI analysis of Elicio Therapeutics Inc (ELTX)
holdElicio Therapeutics Inc is currently not a strong buy due to its recent performance and financial challenges. The stock is priced at $2.84, significantly down from its highs, and the RSI is at 25, indicating oversold conditions. However, the company has a forward P/E ratio of 0, and analysts have set a price target as high as $23, suggesting potential recovery. The main risk is the ongoing clinical trial setbacks, with a net income loss of $11.8 million reported in Q1 2026, which raises concerns about its financial stability.
Bewertungskennzahlen
The current forward P/E ratio for Elicio Therapeutics Inc (ELTX) is 0.00, compared to its 5-year average forward P/E of -2.80.
Alphio AI Price Scenarios for ELTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
7.007-07GlobenewswireElicio Therapeutics Under Investigation for Securities Fraud
8.507-02Yahoo FinanceIdaho Copper Sets Public Offering Price
- 8.507-02stocktwits
Elicio Plans $15 Million Offering to Fund Clinical Development of ELI-002 7P
- 8.507-02NASDAQ.COM
Elicio Therapeutics Raises $15 Million Through Share Offering
- 8.507-02seekingalpha
Elicio Therapeutics Prices $15M Direct Offering to Fund Clinical Development
ELTX FAQ — answered by Alphio AI
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Elicio Therapeutics Inc is currently not a strong buy due to its recent performance and financial challenges. The stock is priced at $2.84, significantly down from its highs, and the RSI is at 25, indicating oversold conditions. However, the company has a forward P/E ratio of 0, and analysts have set a price target as high as $23, suggesting potential recovery. The main risk is the ongoing clinical trial setbacks, with a net income loss of $11.8 million reported in Q1 2026, which raises concerns about its financial stability.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.